drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Adoptive cellular immunotherapy using cryopreserved, non–genetically modified natural killer (NK) cells whose surfaces are covalently conjugated to bispecific IgG antibodies to bridge NK cells to malignant B cells and enhance cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive infusion of cryopreserved, non‑genetically modified NK cells whose surfaces are covalently decorated with bispecific IgG antibodies (CD19/CD20). The tethered antibodies bridge NK cells to malignant B cells, enable dual‑antigen recognition, promote stable immune‑synapse formation, and enhance NK cytotoxicity via degranulation (perforin/granzyme) and Fc receptor–mediated ADCC, thereby killing CD19+/CD20+ lymphoma cells.
drug_name
AcNK-Sup003
nct_id_drug_ref
NCT06693973